Wednesday, February 10, 2010, 8:38am EST - Canadian Markets open in 52 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Cerus Corp. (CERS)

 On Feb 9: 2.1101 USD   0.00 (0.00%)  
MORE ON CERS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Cerus Corporation (NGM:CERS) Delayed quote dataEdit
Pre-Market: 2.33 Up 0.2199 (10.42%) as of 7:05am EST on 02/10/10
Last Trade: 2.1101 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 2.1101
Open: N/A
Bid: 1.30 x 1000
Ask: 2.30 x 3200
1y Target Est: 10.00
Day's Range: N/A - N/A
52wk Range: 0.59 - 3.57
Volume: 9,000
Avg Vol (3m): 407,344
Market Cap: 81.66M
P/E (ttm): N/A
EPS (ttm): -0.994
Div & Yield: N/A (N/A%)
Cerus Corp. (CERS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add CERS to Portfolio   Download Data

HEADLINES
• Cerus enters pact on Intercept system in France
AP (Tue 2:51pm)
• CERUS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue 2:01pm)
• UPDATE - Cerus in development deal for blood safety system
at Reuters (Tue 1:01pm)
• Adoption of Cerus' Technology Makes Its Valuation Look Ridiculous
at Seeking Alpha (Tue 10:36am)
• China BAK, Euro Tech: Early Volume Plays
at TheStreet.com (Tue 10:01am)
• Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell Development
Business Wire (Tue 9:23am)
• Cerus in development deal for blood safety system, shares rise
at Reuters (Tue 9:08am)
• Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells
Business Wire (Mon, Feb 8)
• Cerus to Release Fourth Quarter and Year-End 2009 Results on February 23, 2010
Business Wire (Thu, Feb 4)
• Cerus to Present at 12th Annual BIO CEO & Investor Conference
Business Wire (Tue, Feb 2)
• Biotech Stocks: Drug stocks climb; Cerus, Osteotech gain
at MarketWatch (Thu, Jan 14)
More Headlines for CERS...
ANALYST
EPS Est (next year) (Dec-07) : -1.32
EPS Est (in 2 years) (Dec-08) : -0.87
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Cerus Corporation, a biopharmaceutical company, focuses on the development and commercialization of the INTERCEPT Blood System. The INTERCEPT Blood System, which is based on the proprietary Helinx technology for controlling biological replication,...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices